Pfizer (NYSE:PFE) Trading Up 1.6% – Here’s What Happened

Pfizer Inc. (NYSE:PFE)’s share price traded up 1.6% on Tuesday . The stock traded as high as $27.40 and last traded at $27.2950. 34,599,379 shares were traded during mid-day trading, a decline of 18% from the average daily volume of 42,104,363 shares. The stock had previously closed at $26.87.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Sympathy boost from cancer-vaccine results: Merck and Moderna reported positive Phase 3 melanoma data for their personalized mRNA vaccine combination with Keytruda. The results renewed investor interest in mRNA cancer treatments and lifted Pfizer by association, even though Pfizer was not the company reporting the trial. Pfizer Stock Rises Wednesday: What’s Going On?
• Positive Sentiment: Momentum and options activity: Pfizer broke above its prior April peak and closed near a 52-week high. Investors also purchased 170,284 call options, about 47% above average daily volume, signaling increased short-term bullish interest. Pfizer Breaks to a 52-Week High
• Positive Sentiment: Pipeline catalysts remain supportive: The European Medicines Agency validated Pfizer and Valneva’s filing for their Lyme disease vaccine candidate, allowing the application to proceed to full review. Pfizer is also pursuing obesity treatment potential with monthly berobenatide and retains significant antibody-drug conjugate intellectual property. Pfizer Gets EMA Lyme Vaccine Filing Validation
• Neutral Sentiment: Valuation and performance are attracting scrutiny: Pfizer’s shares have risen strongly over the past month and trade near the top of their 12-month range. That momentum improves sentiment, but it also raises questions about whether near-term gains already reflect expected pipeline and product improvements. Pfizer Faces Fresh Legal Questions
• Negative Sentiment: Legal exposure remains an overhang: A newly announced settlement program involving thousands of Depo-Provera lawsuits alleging intracranial meningiomas could create additional financial exposure and uncertainty for Pfizer. The issue may limit upside if investors become more focused on litigation costs. Pfizer Faces Fresh Legal Questions, Does It Look Fully Valued?

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of research analyst reports. JPMorgan Chase & Co. lowered their target price on Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a report on Wednesday, July 8th. Royal Bank Of Canada upgraded shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price objective for the company in a research report on Tuesday, June 9th. Bank of America lowered their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. BMO Capital Markets cut their target price on Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a research report on Monday, July 13th. Finally, Wall Street Zen upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and an average target price of $28.28.

Pfizer Price Performance

The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The stock has a market capitalization of $158.50 billion, a price-to-earnings ratio of 36.62 and a beta of 0.34. The stock’s 50 day simple moving average is $25.23 and its 200-day simple moving average is $26.23.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the prior year, the business posted $0.78 EPS. Pfizer’s quarterly revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, analysts expect that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.2%. The ex-dividend date is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is 226.32%.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Handelsbanken Fonder AB increased its holdings in shares of Pfizer by 10.4% during the 2nd quarter. Handelsbanken Fonder AB now owns 2,462,431 shares of the biopharmaceutical company’s stock worth $59,295,000 after purchasing an additional 232,528 shares during the period. Vanguard Group Inc. lifted its stake in shares of Pfizer by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock valued at $13,479,520,000 after buying an additional 7,031,162 shares during the period. Leuthold Group LLC acquired a new stake in Pfizer during the second quarter worth about $4,887,000. North Dakota State Investment Board acquired a new stake in Pfizer during the fourth quarter worth about $5,348,000. Finally, PFA Pension Forsikringsaktieselskab bought a new position in Pfizer during the fourth quarter valued at about $76,833,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.